Last Updated: 17 Sep 2024
Executive Summary
NeuroOne Medical Technologies Corp (NMTC) is a medical technology company with a market capitalization of $25.57 million. The company has a strong balance sheet with $0.108 in book value per share. However, the company is currently unprofitable, with a trailing twelve-month EBITDA of -$11.99 million and a diluted EPS of -$0.48. Analysts have a mixed outlook on the company, with one Buy rating and one Hold rating. The analyst target price is $3.15, which represents a potential upside of 289.5% from the current price of $0.81.
Company Overview
NeuroOne Medical Technologies Corporation is a medical technology company that develops, manufactures, and markets medical devices for the treatment of neurological disorders. The company's products include the Quell wearable pain relief device, the Quell Relief Patch, and the Quell App. NeuroOne Medical Technologies is headquartered in Eden Prairie, Minnesota.
Fundamental Analysis
NeuroOne Medical Technologies Corp has a weak financial profile. The company is currently unprofitable, with a trailing twelve-month EBITDA of -$11.99 million and a diluted EPS of -$0.48. The company's gross profit margin is negative, at -77.8%, and its operating margin is -3.38%. NeuroOne Medical Technologies Corp has a strong balance sheet, with $0.108 in book value per share. The company has no debt and $10.2 million in cash and cash equivalents.
Technical Analysis
NeuroOne Medical Technologies Corp's stock price has been in a downtrend since reaching a high of $2.00 in February 2023. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is at 30.54, which indicates that the stock is oversold.
Short Term Outlook
NeuroOne Medical Technologies Corp's stock price is likely to remain under pressure in the short term. The company is currently unprofitable, and analysts have a mixed outlook on the company. The stock is trading below its 50-day and 200-day moving averages, and the RSI is oversold.
Long Term Outlook
NeuroOne Medical Technologies Corp has a strong balance sheet and a pipeline of promising products. The company's Quell wearable pain relief device has shown promising results in clinical trials. If NeuroOne Medical Technologies Corp can successfully commercialize its products, the company could be a long-term winner.
Analyst Recommendations
Analysts have a mixed outlook on NeuroOne Medical Technologies Corp. One analyst has a Buy rating on the stock, while another analyst has a Hold rating. The analyst target price is $3.15, which represents a potential upside of 289.5% from the current price of $0.81.
